Real-World Experience of efficacy and safety of trabectedin in patients with soft tissue sarcoma: a bicentric retrospective analysis.

Fiche publication


Date publication

octobre 2022

Journal

Oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr CHAIGNEAU Loïc, Pr NERICH Virginie, Dr HERVIEU Alice, Dr CHARON-BARRA Céline


Tous les auteurs :
Chaigneau L, Jary M, Nerich V, Hervieu A, Aubry S, Charon Barra C, Meynard G, Neumann F, Kalbacher E, Isambert N

Résumé

Soft tissue sarcomas (STS) are a rare and heterogenous group of tumors, with poor prognostic, judging from their frequency to relapse. Few drugs are available after the conventional first line regimen. Since 2007, trabectedin got approval after failure of anthracyclines and ifosfamide, for advanced or metastatic STS. This led to a FDA approval in 2015, but real-world evidence are still required, complementary to the pivotal phase II and III trials.

Référence

Oncology. 2022 10 25;: